MCID: BRD004
MIFTS: 50

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 72 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD10 32 F60.3
ICD9CM 34 301.83
MeSH 41 D001883
NCIt 46 C92633
SNOMED-CT 64 192488005 20010003
UMLS 69 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to antisocial personality disorder and alexithymia. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Neuroscience and Circadian rythm related genes. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and bone, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 72 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD),... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 antisocial personality disorder 30.5 COMT MAOA SLC6A4
2 alexithymia 30.5 COMT HTR1A SLC6A4
3 social phobia 30.2 MAOA SLC6A4
4 substance dependence 30.1 BDNF HTR1B MAOA SLC6A4
5 conduct disorder 30.1 COMT MAOA SLC6A4 TPH1
6 intermittent explosive disorder 30.0 HTR1A SLC6A4
7 eating disorder 30.0 BDNF COMT HTR2C SLC6A4
8 dysthymic disorder 29.9 HTR2A MAOA SLC6A4
9 bulimia nervosa 2 29.8 BDNF COMT HTR2A SLC6A4
10 schizoaffective disorder 29.6 BDNF COMT HTR2A SLC6A4
11 bulimia nervosa 1 29.6 BDNF COMT HTR1B HTR2A MAOA SLC6A4
12 oppositional defiant disorder 29.5 COMT MAOA SLC6A4 TPH2
13 substance abuse 29.5 BDNF COMT HTR1B MAOA SLC6A4
14 personality disorder 29.2 BDNF COMT HTR1A HTR1B HTR2A HTR2C
15 generalized anxiety disorder 28.9 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
16 bipolar i disorder 28.9 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
17 post-traumatic stress disorder 28.5 BDNF COMT FKBP5 HTR2A MAOA NR3C1
18 psychotic disorder 28.4 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
19 disease of mental health 28.3 BDNF COMT HTR1A HTR2A HTR2C MAOA
20 bipolar disorder 27.7 BDNF COMT HTR1A HTR2A HTR2C MAOA
21 attention deficit-hyperactivity disorder 27.7 BDNF COMT HTR1A HTR1B HTR2A HTR2C
22 panic disorder 27.5 BDNF COMT HTR1A HTR2A HTR2C MAOA
23 schizophrenia 27.5 BDNF COMT HTR1A HTR1B HTR2A HTR2C
24 anxiety 27.4 BDNF COMT HTR1A HTR2A HTR2C MAOA
25 mood disorder 27.0 BDNF COMT HTR1A HTR1B HTR2A HTR2C
26 major depressive disorder 26.5 BDNF COMT FKBP5 HTR1A HTR1B HTR2A
27 alcohol dependence 26.2 BDNF COMT HTR1A HTR1B HTR2A HTR2C
28 multiple personality disorder 11.3
29 impulse control disorder 10.9
30 childhood-onset schizophrenia 10.4 COMT TPH1
31 atypical depressive disorder 10.4 MAOA SLC6A4
32 alzheimer disease 5 10.4 HTR2A SLC6A4
33 phobia, specific 10.4 COMT MAOA
34 alcoholic psychosis 10.3 HTR2A SLC6A4
35 schizophrenia 5 10.3 HTR1A HTR2A
36 tardive dyskinesia 10.3 COMT HTR2A
37 bruxism 10.3 HTR2A SLC6A4
38 schizoid personality disorder 10.3 HTR1A HTR2A
39 hypoactive sexual desire disorder 10.3 HTR1A HTR2A
40 substance-induced psychosis 10.3 HTR1A HTR2A
41 specific developmental disorder 10.2 BDNF COMT SLC6A4
42 autoimmune polyendocrine syndrome type 1 10.2 TPH1 TPH2
43 dystonia 1, torsion, autosomal dominant 10.2 COMT MAOA
44 drug-induced mental disorder 10.2 HTR1A HTR2A
45 traumatic brain injury 10.2 BDNF COMT
46 kleptomania 10.2 HTR1A MAOA SLC6A4
47 blood group, i system 10.2
48 episodic pain syndrome, familial, 1 10.2
49 agoraphobia 10.2 HTR1A MAOA SLC6A4
50 pathological gambling 10.2 HTR2A MAOA SLC6A4

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

MGI Mouse Phenotypes related to Borderline Personality Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 BDNF COMT FKBP5 HTR1A HTR1B HTR2A
2 cardiovascular system MP:0005385 9.86 COMT HTR1A HTR1B MAOA NR3C1 SLC6A4
3 homeostasis/metabolism MP:0005376 9.85 BDNF COMT FKBP5 HTR1A HTR2C MAOA
4 adipose tissue MP:0005375 9.77 HTR1B HTR2C NR3C1 TPH1 TPH2
5 muscle MP:0005369 9.43 HTR1B HTR2A HTR2C NR3C1 SLC6A4 TPH1
6 nervous system MP:0003631 9.23 BDNF COMT HTR1A HTR2C MAOA NR3C1

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
3
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
7 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
8 Serotonin Agents Phase 4,Phase 3,Phase 2
9 Serotonin Antagonists Phase 4,Phase 2
10 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
11 Muscarinic Antagonists Phase 4,Phase 2
12 Cholinergic Agents Phase 4,Phase 2
13 Cholinergic Antagonists Phase 4,Phase 2
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
15 Tranquilizing Agents Phase 4,Phase 3,Phase 2
16 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
17 Parasympatholytics Phase 4,Phase 2
18 Dopamine Agents Phase 4,Phase 2
19 Dopamine Antagonists Phase 4,Phase 2
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
21 Antidepressive Agents Phase 4,Phase 2
22 Antidepressive Agents, Second-Generation Phase 4,Phase 2
23 Psychotropic Drugs Phase 4,Phase 3,Phase 2
24 Antipsychotic Agents Phase 4,Phase 3,Phase 2
25 Autonomic Agents Phase 4,Phase 3,Phase 2
26 Antiparkinson Agents Phase 4,Phase 2
27 calcium channel blockers Phase 4
28 Sodium Channel Blockers Phase 4
29 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Anticonvulsants Phase 4,Phase 3
33 Excitatory Amino Acid Antagonists Phase 4,Phase 2
34 Excitatory Amino Acids Phase 4,Phase 2
35 Calcium, Dietary Phase 4
36 Omega 3 Fatty Acid Nutraceutical Phase 4
37
Ethanol Approved Phase 3,Phase 2 64-17-5 702
38
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 5195 26757
39
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
40
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2 16590-41-3 5360515
41 Quetiapine Fumarate Phase 3,Phase 2 111974-72-2
42 Narcotic Antagonists Phase 3,Phase 2
43 Narcotics Phase 3,Phase 2
44 Gastrointestinal Agents Phase 3
45 Antiemetics Phase 3
46 Anti-Infective Agents Phase 3,Phase 2,Phase 1
47 Anti-Infective Agents, Local Phase 3,Phase 2
48 Protective Agents Phase 3,Phase 2,Phase 1
49
Acetaminophen Approved Phase 2 103-90-2 1983
50
Ziprasidone Approved Phase 2 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 142)

# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
4 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
5 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
6 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
7 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
8 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
9 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
10 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
11 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo
12 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Completed NCT00088036 Phase 3 Olanzapine
13 Naltrexone in Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
14 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
15 Acetaminophen and Social Processes Unknown status NCT02108990 Phase 2 Acetaminophen
16 Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment Completed NCT02125942 Phase 1, Phase 2
17 Ziprasidone in the Treatment of Borderline Personality Disorder Completed NCT00635921 Phase 2 ziprasidone;Placebo
18 Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Completed NCT01103180 Phase 2 Escitalopram
19 Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
20 Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder Completed NCT00145678 Phase 2
21 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
22 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
23 Treatment of Suicidal Women With Borderline Personality Disorder Completed NCT00183651 Phase 2
24 Oxytocin as Adjunctive Therapy for Schizophrenia Completed NCT01699997 Phase 2 Oxytocin;Placebo
25 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
26 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
27 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2 incobotulinumtoxin A
28 Ketamine in Borderline Personality Disorder Recruiting NCT03395314 Phase 2 Ketamine;Midazolam
29 A Novel Drug for Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
30 Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Recruiting NCT01212588 Phase 2 mifepristone;Placebo
31 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
32 Brexpiprazole in Borderline Personality Disorder Not yet recruiting NCT03418675 Phase 2 Rexulti;Placebo
33 Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder Not yet recruiting NCT03209102 Phase 2
34 N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
35 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
36 Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder Unknown status NCT00269139 Phase 1
37 20 Weeks DBT Group Skills Training Study Completed NCT01193205 Phase 1
38 Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents Completed NCT01111734 Phase 1 fMRI
39 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
40 Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Unknown status NCT01602497
41 Event Related Potentials in Borderline Personality Disorder and Major Depression Unknown status NCT01469663
42 CPT Group for DBT Clients With Co-Occurring Borderline Personality Disorder and PTSD Unknown status NCT02574429
43 Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention Unknown status NCT01531634
44 Guanfacine to Treat Borderline Personality Disorder Unknown status NCT00358969 guanfacine (Tenex)
45 A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder Unknown status NCT01033708
46 Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder Unknown status NCT00131781
47 A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults Unknown status NCT01426984 methylphenidate
48 DBT in Borderline Personality Disorder Unknown status NCT00252031
49 DBT and Escitalopram in Borderline Personality Disorder Unknown status NCT00255554 Escitalopram
50 Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder Unknown status NCT01683136

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

38
Brain, Amygdala, Bone, Testes, Pituitary, Ovary, Cortex

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 748)
# Title Authors Year
1
Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. ( 29448136 )
2018
2
The rewarding nature of provocation-focused rumination in women with borderline personality disorder: a preliminary fMRI investigation. ( 29372058 )
2018
3
Behavioural mimicry and loneliness in borderline personality disorder. ( 29407356 )
2018
4
Treating borderline personality disorder with oxytocin: An enthusiastic note of caution. Commentary to Servan et al. The effect of oxytocin in borderline personality disorder. ( 29402386 )
2018
5
Psychosocial stress differentially affects emotional empathy in women with borderline personality disorder and healthy controls. ( 29417987 )
2018
6
Transient hallucinations during interpersonal stress in an adolescent with borderline personality disorder. ( 29374970 )
2018
7
Reduced white matter integrity in borderline personality disorder: A diffusion tensor imaging study. ( 28922736 )
2018
8
Book Review: Integrated Modular Treatment for Borderline Personality Disorder: A Practical Guide to Combining Effective Treatment Methods Integrated Modular Treatment for Borderline Personality Disorder: A Practical Guide to Combining Effective Treatment Methods . Livesley W. John . Cambridge (UK) : Cambridge University Press ; 2017 . 297 p. US$66.50 . Paperback. ISBN 978-1-10-67974-0 . Reviewer rating: Excellent. ( 29433334 )
2018
9
Alliance Rupture and Resolution in Dialectical Behavior Therapy for Borderline Personality Disorder. ( 29388901 )
2018
10
Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study. ( 29402870 )
2018
11
Change in Biased Thinking in a Treatment Based on the Motive-Oriented Therapeutic Relationship for Borderline Personality Disorder. ( 29388899 )
2018
12
The Role of Negative Affect and Self-Concept Clarity in Predicting Self-Injurious Urges in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 29388895 )
2018
13
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
14
Attachment-Related Regulatory Processes Moderate the Impact of Adverse Childhood Experiences on Stress Reaction in Borderline Personality Disorder. ( 29388902 )
2018
15
Opioid addiction and borderline personality disorder. ( 29283477 )
2018
16
Variability in phase and amplitude of diurnal rhythms is related to variation of mood in bipolar and borderline personality disorder. ( 29374207 )
2018
17
Clinical Components of Borderline Personality Disorder and Personality Functioning. ( 29393279 )
2018
18
Differential relations of executive functioning to borderline personality disorder presentations in adolescents. ( 29388349 )
2018
19
Assessing advanced theory of mind and alexithymia in patients suffering from enduring borderline personality disorder. ( 29360051 )
2018
20
Borderline personality disorder and sexual abuse: A systematic review. ( 29407572 )
2018
21
Affect dysregulation, psychoform dissociation, and adult relational fears mediate the relationship between childhood trauma and complex posttraumatic stress disorder independent of the symptoms of borderline personality disorder. ( 29410773 )
2018
22
On the potential for iatrogenic effects of psychiatric crisis services: The example of dialectical behavior therapy for adult women with borderline personality disorder. ( 29369662 )
2018
23
Fear of Being Laughed at in Borderline Personality Disorder. ( 29410640 )
2018
24
Predicting Nonsuicidal Self-Injury in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 28072044 )
2017
25
The Relationship between Survival Sex and Borderline Personality Disorder Symptoms in a High Risk Female Population. ( 28885558 )
2017
26
The specificity of emotion dysregulation in adolescents with borderline personality disorder: comparison with psychiatric and healthy controls. ( 28078089 )
2017
27
People with Borderline Personality Disorder and Burns: Some Considerations for Health Professionals. ( 28945490 )
2017
28
Compelled to Risk: Does Sexual Compulsivity Explain the Connection Between Borderline Personality Disorder Features and Number of Sexual Partners? ( 28072043 )
2017
29
Estimating the prevalence of borderline personality disorder in mothers involved in youth protection services. ( 28944592 )
2017
30
Altered Empathy for Psychological and Physical Pain in Borderline Personality Disorder. ( 28072040 )
2017
31
Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. ( 28086181 )
2017
32
Resting cardiac function in adolescent non-suicidal self-injury: The impact of borderline personality disorder symptoms and psychosocial functioning. ( 28039803 )
2017
33
Substance Use in Youth With Borderline Personality Disorder. ( 28926304 )
2017
34
"Abandonment Psychotherapy" for Suicidal Patients with Borderline Personality Disorder: Long-Term Outcome. ( 28903102 )
2017
35
Comorbidity study of borderline personality disorder: applying association rule mining to the Taiwan national health insurance research database. ( 28077135 )
2017
36
The overlap between autistic spectrum conditions and borderline personality disorder. ( 28886113 )
2017
37
Associations of borderline personality disorder traits with stressful events and emotional reactivity in women with bulimia nervosa. ( 28691843 )
2017
38
Pain Perception and Body Awareness Among Individuals With Borderline Personality Disorder. ( 28902571 )
2017
39
Contrasting metacognitive, social cognitive and alexithymia profiles in adults with borderline personality disorder, schizophrenia and substance use disorder. ( 28826064 )
2017
40
A Mother's Borderline Personality Disorder and Her Sensitivity, Autonomy Support, Hostility, Fearful/Disoriented Behavior, and Role Reversal With Her Young Child. ( 28072039 )
2017
41
Substance Misuse Is Associated With Increased Psychiatric Severity Among Treatment-Seeking Individuals With Borderline Personality Disorder. ( 28910215 )
2017
42
Personality organization and its association with clinical and functional features in borderline personality disorder. ( 28923434 )
2017
43
Determining if Borderline Personality Disorder and Bipolar Disorder Are Alternative Expressions of the Same Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. ( 28922592 )
2017
44
Outcome Trajectories and Prognostic Factors for Suicide and Self-Harm Behaviors in Patients With Borderline Personality Disorder Following One Year of Outpatient Psychotherapy. ( 28910214 )
2017
45
Narrative self-appropriation: embodiment, alienness, and personal responsibility in the context of borderline personality disorder. ( 28895019 )
2017
46
Insomnia in adult attention-deficit/hyperactivity disorder: A comparison with borderline personality disorder population in a clinical setting and control participants. ( 28501733 )
2017
47
Change of Unresolved Attachment in Borderline Personality Disorder: RCT Study of Transference-Focused Psychotherapy. ( 28903103 )
2017
48
Subgroups of Adolescent Girls With Borderline Personality Disorder Symptoms. ( 28926303 )
2017
49
Comparing Facial Emotional Recognition in Patients with Borderline Personality Disorder and Patients with Schizotypal Personality Disorder with a Normal Group. ( 28659980 )
2017
50
Face and gaze perception in borderline personality disorder: An electrical neuroimaging study. ( 28941875 )
2017

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1 12.29 COMT HTR1A TPH1 TPH2
3
Show member pathways
12.02 BDNF HTR1A HTR1B
4 11.97 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
5
Show member pathways
11.93 MAOA TPH1 TPH2
6
Show member pathways
11.73 HTR1A HTR1B HTR2A HTR2C
7 11.61 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
8
Show member pathways
11.21 MAOA SLC6A4 TPH2
9
Show member pathways
10.99 TPH1 TPH2
10
Show member pathways
10.91 COMT MAOA SLC6A4
11 10.8 HTR2A HTR2C
12
Show member pathways
10.78 COMT MAOA TPH1
13 10.67 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
14
Show member pathways
10.65 COMT MAOA
15 10.58 COMT MAOA

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.1 HTR1A HTR1B HTR2A HTR2C NRXN3 SLC6A4

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.84 HTR1B HTR2A HTR2C NRXN3
2 response to drug GO:0042493 9.77 COMT HTR1B HTR2A HTR2C SLC6A4
3 circadian rhythm GO:0007623 9.76 SLC6A4 TPH1 TPH2
4 positive regulation of fat cell differentiation GO:0045600 9.67 HTR2A HTR2C TPH1
5 behavioral fear response GO:0001662 9.61 HTR1A HTR2C
6 regulation of dopamine secretion GO:0014059 9.61 HTR1B HTR2A
7 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.6 HTR1B HTR2A
8 bone remodeling GO:0046849 9.59 HTR1B TPH1
9 neurotransmitter catabolic process GO:0042135 9.58 COMT MAOA
10 catecholamine metabolic process GO:0006584 9.57 COMT MAOA
11 aromatic amino acid family metabolic process GO:0009072 9.56 TPH1 TPH2
12 dopamine catabolic process GO:0042420 9.55 COMT MAOA
13 regulation of hormone secretion GO:0046883 9.52 HTR1A HTR2A
14 indolalkylamine biosynthetic process GO:0046219 9.51 TPH1 TPH2
15 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.5 HTR1A HTR1B HTR2A
16 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.48 HTR2A HTR2C
17 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.46 HTR1A HTR1B
18 serotonin biosynthetic process GO:0042427 9.43 TPH1 TPH2
19 vasoconstriction GO:0042310 9.43 HTR1A HTR1B SLC6A4
20 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.4 HTR2A HTR2C
21 regulation of behavior GO:0050795 9.33 HTR1A HTR1B HTR2A
22 serotonin receptor signaling pathway GO:0007210 9.13 HTR1A HTR2A HTR2C
23 behavior GO:0007610 8.92 HTR1A HTR1B HTR2A HTR2C

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.73 HTR1A HTR1B HTR2A HTR2C
2 drug binding GO:0008144 9.58 HTR1B HTR2A HTR2C
3 neurotransmitter receptor activity GO:0030594 9.46 HTR1A HTR1B HTR2A HTR2C
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.37 TPH1 TPH2
5 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.32 HTR2A HTR2C
6 tryptophan 5-monooxygenase activity GO:0004510 9.26 TPH1 TPH2
7 G-protein coupled serotonin receptor activity GO:0004993 9.26 HTR1A HTR1B HTR2A HTR2C
8 serotonin binding GO:0051378 8.92 HTR1A HTR1B HTR2A HTR2C

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....